ArticleFrontiers in pediatrics2026
Familial, constitutional, and combined idiopathic short stature: longitudinal growth patterns and pubertal effects.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pathological causes account for approximately 15%-20% of short-stature cases, whereas about 80% of short-statured children have no identifiable underlying etiology and are classified as idiopathic short stature (ISS). ISS represents a highly heterogeneous group, and ongoing debates persist due to the limited availability of observational data and advances in genetic research. Despite its high prevalence, long-term auxological data comparing familial, constitutional, and combined variants across pubertal stages remain limited. Objectives: Our study aimed to characterize the clinical and laboratory features at presentation and to evaluate the longitudinal growth patterns of children initially diagnosed with ISS. Methods: A retrospective cohort of 171 children with ISS (46.2% female) was analyzed. Participants were classified as prepubertal (Group 1; Results: Mean age at first evaluation was 7.94 ± 4.46 years; mean height SDS was -2.45 ± 0.34 with proportionate body proportions and normal birth parameters. Bone age averaged 6.57 ± 4.28 years (≈1.4-year delay). The prepubertal/pubertal distribution was 121 (70.8%) vs. 50 (29.2%); combined phenotypes comprised 53.5% of the cohort. Over 1.85 ± 1.40 years of follow-up, mean ΔHeight SDS was +0.35 ± 0.56; pubertal subgroups, particularly 2b and 2c, showed the most significant gains (ΔHeight SDS +0.58 and +0.53; both Conclusions: ISS subtypes display distinct auxological courses. Bone-age delay is a key predictor of subsequent catch-up growth, most evident in pubertal CDGP and combined phenotypes. Given the high rate of spontaneous improvement, especially after pubertal onset, careful longitudinal monitoring should precede pharmacologic therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.